Log in to search using one of your social media accounts:

Portola shares soar after FDA approves clot preventing drug
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Portola blood-thinner to prevent clots
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. FDA approves Portola blood-thinner to prevent clots
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. FDA approves Portola blood-thinner to prevent blood clots
(Reuters) - The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Bevyxxa (betrixaban) for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients
SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc. ® (Nasdaq:PTLA) today announced the U.S. Food and Drug Administration (FDA) has approved Bevyxxa (betrixaban), the first and only anticoagulant for hospital... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 23, 2017 Category: Drugs & Pharmacology Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 19, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Medtronic touts retrospective data in Reactive ATP therapy AF study Medtronic‘s today released data from a retrospective analysis of patients with its Reactive ATP therapy, touting slowed atrial fibrillation progression f...
Source: Mass Device - June 19, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Absorb BVS Safety Problems Keep Growing (CME/CE)
(MedPage Today) -- Is bad implantation technique really the source of stent thrombosis? (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 19, 2017 Category: Consumer Health News Source Type: news

Study: Ekos ultrasound device provides relief to patients with chronic deep vein thrombosis
BTG (LON:BTG) touted data last week showing that patients with chronic deep vein thrombosis and post-thrombotic syndrome can be safely and effectively treated with the Ekos device and anti-coagulation drugs. The study’s protocol is the 1st treatment regimen proven to reduce the symptoms of PTS and demonstrate an improvement in quality of life for patients with DVT. Get the full story at our sister site, Drug Delivery Business News. The post Study: Ekos ultrasound device provides relief to patients with chronic deep vein thrombosis appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 19, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Vascular BTG Source Type: news

Study: Researchers create ‘ ultrasound drill ’ to attack thrombosis
Researchers have developed a new surgical tool which uses low-frequency intravascular ultrasound to break down blood clots which could cause deep vein thrombosis. The ultrasound “drill”, called that because it can be aimed directly ahead, could allow physicians to better target clots and reduce treatment time, according to researchers from North Carolina State University and the University of North Carolina at Chapel Hill. Read the whole story at our sister site, Medical Design & Outsourcing   The post Study: Researchers create ‘ultrasound drill’ to attack thrombosis appeared first on MassD...
Source: Mass Device - June 14, 2017 Category: Medical Devices Authors: Fink Densford Tags: Catheters Research & Development Vascular Source Type: news

New ultrasound 'drill' targets deep vein blood clots
(North Carolina State University) Researchers have developed a new surgical tool that uses low-frequency intravascular ultrasound to break down blood clots that cause deep vein thrombosis. The tool is the first ultrasound 'drill' that can be aimed straight ahead, allowing doctors to better target clots -- which holds promise for significantly reducing treatment time. To date, the technology has been tested only in synthetic blood vessels. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 14, 2017 Category: Biology Source Type: news

Snake venom is key ingredient in experimental drug for heart patients
An experimental antiplatelet drug has surprising bite. Based on a protein found in snake venom, the new drug prevented blood clotting in mice without causing excessive bleeding after an injury, according to research published Thursday in the journal Arteriosclerosis, Thrombosis and Vascular Biology. The drug has yet to be tested in humans. (Source: CNN.com - Health)
Source: CNN.com - Health - June 8, 2017 Category: Consumer Health News Source Type: news

Snake venom is key ingredient in experimental antiplatelet drug
An experimental antiplatelet drug has surprising bite. Based on a protein found in snake venom, the new drug prevented blood clotting in mice without causing excessive bleeding after an injury, according to research published Thursday in the journal Arteriosclerosis, Thrombosis and Vascular Biology. The drug has yet to be tested in humans. (Source: CNN.com - Health)
Source: CNN.com - Health - June 8, 2017 Category: Consumer Health News Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 7, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Court approves Halt Medical’s bankruptcy sale A Delaware state judge this week approved the bankruptcy sale of Halt Medical designed to keep its Acessa uterine fibroid treatment on the market. The Brentwood, Calif.-based ...
Source: Mass Device - June 7, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Amaranth Medical looks to recapture the potential of bioresorbable scaffolds
Dr. Antonio Colombo had finished his presentation of 9-month data for Amaranth Medical‘s Aptitude sirolimus-eluting bioresorbable scaffold when an audience member asked about adverse events. He told the EuroPCR attendee that they hadn’t seen any adverse events related to the device during the trial – and that’s unusual. Bioresorbable scaffolds, like Abbott‘s (NYSE:ABT) Absorb, have been plagued with a myriad of troubling data suggesting that the technology is linked to thrombosis and target lesion failure. Newly-developed scaffolds are only just beginning to live up to thin-stru...
Source: Mass Device - June 7, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Stents Vascular Wall Street Beat Amaranth Medical Source Type: news

Utility of Hemoccult Testing Before Anticoagulation in VTE Utility of Hemoccult Testing Before Anticoagulation in VTE
Does fecal occult blood testing prior to initiating anticoagulation therapy in patients with a new diagnosis of venous thromboembolism provide a useful assessment of GI bleeding risk?Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 7, 2017 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Rivaroxaban vs. Warfarin in a Patient With AF and LAA Thrombus Rivaroxaban vs. Warfarin in a Patient With AF and LAA Thrombus
This case highlights the possibility of using rivaroxaban as a safe and effective alternative to warfarin in complex cases involving certain thrombophilic conditions.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 2, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Good News From the Far East for Beleaguered Absorb Scaffold Good News From the Far East for Beleaguered Absorb Scaffold
Scaffold thrombosis, an Achilles'heel of the device, occurred in just one patient between years 2 and 3 in ABSORB JAPAN and ABSORB CHINA.Heartwire from Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Stago closes HemoSonics buy
Stago Group said today that it completed its acquisition of point-of-care blood diagnostics platform developer HemoSonics. Charlottesville, Va.-based HemoSonics developed the Quanta Hemostasis Analyzer, which is designed to measure treatable aspects of hemostasis in approximately 15 minutes using its sonic estimation of elasticity via resonance (SEER) technology. Financial details of the acquisition were not disclosed. The transaction is part of Stago’s efforts to diversity its portfolio of medical devices, according to the company. “This significant step makes us very proud to contribute to the management of h...
Source: Mass Device - May 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Blood Management Diagnostics Mergers & Acquisitions Wall Street Beat HemoSonics Source Type: news

Bioprosthetic Valve Thrombosis Bioprosthetic Valve Thrombosis
This article reviews the diagnostic challenges of bioprosthetic valve thrombosis, and details available therapeutic options, particularly within the rapidly expanding field of TAVR.Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 29, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Jefferson researcher identifies targets for better anti-thrombotic medicine
(Thomas Jefferson University) Blood thinners, such as aspirin, reduce the risk of thrombus formation but also interfere with the initial clot formation that is essential for preventing blood loss from the wounds. Now researchers have discovered that a molecule plays a role in thrombus development, but not the initial clot formation, suggesting a new avenue for developing more specific and protective blood thinners. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 24, 2017 Category: International Medicine & Public Health Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 22, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. BoneSupport launches trial of antibiotic-eluting bone graft BoneSupport said today that the 1st patient has been enrolled in the pivotal investigational device exemption trial for its injectable antibiotic-eluting bone graft su...
Source: Mass Device - May 22, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

EuroPCR Roundup: Bioresorbable stents show promise, but metallic drug-eluting stents remain standard
Abbott‘s (NYSE:ABT) bioresorbable scaffold has been plagued with a myriad of troubling data, including a study that showed that the device is associated with an increase in thrombosis and target lesion failure. In April, Abbott pulled the stent from European markets. In response to widespread criticism of the technology, the EuroPCR team released a statement this week defending bioresorbable stents as “an important option to optimise outcomes in patients whose needs are not adequately met with current devices.” Get the full story at our sister site, Drug Delivery Business News. The post EuroPCR Round...
Source: Mass Device - May 22, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Stents Wall Street Beat Abbott Source Type: news

BTG touts Ekos data from pulmonary embolism trial
BTG (LON:BTG) touted data today from the Optalyse PE trial showing that pulmonary embolism can be treated effectively with Ekos over a shorter period and with smaller doses of thrombolytic drugs compared to the current standard. The 101-patient trial randomized participants to receive therapeutic anticoagulation and Ekos acoustic pulse thrombolysis therapy at different doses for different lengths of time. The 1st group received 4 milligrams per catheter of tissue plasminogen activator over 2 hours, while the 2nd cohort received the same dose over 4 hours. The 3rd group was treated with 6 milligrams per catheter o...
Source: Mass Device - May 22, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Wall Street Beat BTG Source Type: news

Perioperative Aspirin for Venous Thromboembolism Prevention Perioperative Aspirin for Venous Thromboembolism Prevention
This study investigated whether perioperative aspirin is effective in the prevention of post-surgical venous thromboembolism, including deep vein thrombosis and pulmonary embolism.Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 22, 2017 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

New therapy for atherosclerosis developed by Ben-Gurion University
(American Associates, Ben-Gurion University of the Negev) 'Our E-selectin-targeting polymer reduces existing plaque and prevents further plaque progression and inflammation, preventing arterial thrombosis, ischemia, myocardial infarction, and stroke,' says Prof. Ayelet David of the BGU Department of Clinical Biochemistry and Pharmacology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 22, 2017 Category: International Medicine & Public Health Source Type: news

NOR-TEST: Tenecteplase Similar to Alteplase in Stroke NOR-TEST: Tenecteplase Similar to Alteplase in Stroke
The newer thrombolytic given as a bolus dose showed functional and safety outcomes similar to those of alteplase infusion in the NOR-TEST trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 19, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Invitation: Roche Analyst Event at ISTH 2017
We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Haemostasis Congress (ISTH) in Berlin 8 – 13 July 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - May 18, 2017 Category: Pharmaceuticals Source Type: news

Very Late BVS Thrombosis Not Ruled Out in Asian Studies
(MedPage Today) -- No scaffold thrombosis cases after 2 years in Absorb China but one seen in Japan (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 16, 2017 Category: Cardiology Source Type: news

Abbott recalls heart catheters on balloon sheath issue
Abbott (NYSE:ABT) is recalling some 450,000 coronary catheters on the risk that removing a protective balloon sheath can damage the ballon during angioplasty procedures. In a March 22 letter to customers, Abbot said the recall affects its NC Trek RX and NC Traveler RX coronary dilatation catheters and the NC Tenku RX PTCA balloon catheter. “Product from the identified lots may exhibit difficulty in removing the protective balloon sheath which can result in issues with inflating or deflating the balloon,” Abbott said. “If excessive force is required to remove the balloon sheath, the sheath m...
Source: Mass Device - May 16, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Food & Drug Administration (FDA) Recalls Regulatory/Compliance Abbott Source Type: news

Prevalence of VTE in Syncope Patients Low; Routine Testing Unwarranted Prevalence of VTE in Syncope Patients Low; Routine Testing Unwarranted
Less than 2% of patients hospitalized with syncope have venous thromboembolism (VTE), hint results of a new study from Canada.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 11, 2017 Category: Radiology Tags: Emergency Medicine News Source Type: news

New VTE Often Occurs During Chemo in Ovarian Cancer
Most cases of venous thromboembolism occurred during neoadjuvant or adjuvant chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 11, 2017 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Nursing, Oncology, Surgery, Journal, Source Type: news

Ovarian Cancer: Clot Risk High in All Phases of Treatment Ovarian Cancer: Clot Risk High in All Phases of Treatment
A new study highlights the risk for thrombosis in women with ovarian cancer during all phases of treatment, suggesting there is a potential crisis in undertreatment.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 10, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

New Strategy Cuts Hospital-Acquired VTEs New Strategy Cuts Hospital-Acquired VTEs
Combining a risk-assessment tool and a prevention strategy for venous thromboembolism (VTE) reduced hospital-acquired events by 22%, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 10, 2017 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Save the date: Roche Analyst Event at ISTH 2017
We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - May 4, 2017 Category: Pharmaceuticals Source Type: news

Deep vein thrombosis symptoms - do THIS to reduce risk of deadly DVT
DEEP vein thrombosis - also known as DVT - is a blood clot that develops within a deep vein in the body, usually in the leg and can sometimes cause symptoms such as leg pain. However, an expert has revealed smoking could make the condition worse. (Source: Daily Express - Health)
Source: Daily Express - Health - May 2, 2017 Category: Consumer Health News Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 1, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Abbott wins $11m DoD contract for brain injury diagnostic dev Abbott won an $11.3 million contract with the US Department of Defense for the development of traumatic brain injury assays, according to a DoD released last Friday....
Source: Mass Device - May 1, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Cardinal Health ’ s fiscal Q3 earnings top forecast, but sales miss the mark
Fiscal 3rd-quarter earnings for Cardinal Health (NYSE:CAH) came in ahead of the consensus estimate on Wall Street, but the top line missed expectations by nearly $500 million. The Dublin, Ohio-based company posted profits of $381 million, or $1.20 per share, on sales of $31.82 billion for the 3 months ended March 31, for a bottom-line slide of-1.3% on sales growth of 3.8% compared with Q3 2016. Adjusted to exclude 1-time items, earnings per share were $1.53, 7¢ ahead of the consensus on The Street. But analysts there were looking for sales of $32.30 billion. CAH shares were down -1.0% to $71.85 apiece today ...
Source: Mass Device - May 1, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Cardinal Health Source Type: news

Medtronic wins FDA nod for Resolute Onyx drug-eluting stent
Medtronic (NYSE:MDT) said today that the FDA approved its Resolute Onyx drug-eluting stent. The Fridley, Minn.-based company touted its device as the 1st stent formed by a sinusoidal wave of cobalt alloy wire. The company incorporated a radiopaque inner core within the wire to boost visibility, according to Medtronic. The stent also features thin struts and a polymer blend that minimizes inflammation and risk of stent thrombosis. Get the full story at our sister site, Drug Delivery Business News. The post Medtronic wins FDA nod for Resolute Onyx drug-eluting stent appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 1, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Drug-Eluting Stents Food & Drug Administration (FDA) Vascular Wall Street Beat Medtronic Source Type: news

Legal Briefs: Was the Intracardiac Thrombus Secondary to an Unnecessary Umbilical Venous Catheter?
(Source: NeoReviews recent issues)
Source: NeoReviews recent issues - May 1, 2017 Category: Pediatrics Authors: Sims, M. E. Tags: Pediatric Drug Labeling Update Index of Suspicion in the Nursery Source Type: news

Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA Based on EINSTEIN CHOICE Data, Which Showed Superiority with XARELTO ® (rivaroxaban) Versus Aspirin in Reducing Risk of Recurrent Venous Thromboembolism (VTE), with Low Rates of Major Bleeding Across Groups
Filing seeks update to prescribing information to include additional dosage of XARELTO ® to reduce risk of recurrent VTE (Source: Johnson and Johnson)
Source: Johnson and Johnson - April 28, 2017 Category: Pharmaceuticals Source Type: news

Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism (for specialized target groups only)
If approved, rivaroxaban 10 mg once daily will provide an additional treatment option alongside the already approved rivaroxaban 20 mg once-daily dose / Risk of recurrent thrombosis is up to 10% in the first year if anticoagulation therapy is stopped / Application to FDA supported by data from the EINSTEIN CHOICE study (Source: Bayer Company News)
Source: Bayer Company News - April 28, 2017 Category: Pharmaceuticals Source Type: news

Novel ultrasound device dev Sonavex raises $3m
John Hopkins spin-out Sonavex said today it raised $3 million in financing, including a $2.2 million closed Series A round to support its novel ultrasound technology. The round was led by Grey Sky Venture Partners and joined by CRCM Venture Capital, Tedco, the Abell Foundation and individual investors, the Baltimore, Md.-based company said. The round was also expanded by $1.3 million “following increased demand from investors,” Sonavex added. “This represents an exciting time for the company. Our traction has enabled Sonavex to not only raise capital to accomplish critical milestones, but also attrac...
Source: Mass Device - April 24, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Ultrasound sonavex Source Type: news

Sleep Studies and VTEs Headline Hospitalists Meeting Sleep Studies and VTEs Headline Hospitalists Meeting
Curbing interruptions to patient's sleep and a rare look into hospital-associated venous thromboembolism (VTEs) will be among the hot topics at the upcoming Society of Hospital Medicine meeting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 24, 2017 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Abbott issues select recall for NC coronary dilation & balloon caths
Abbott (NYSE:ABT) has issued an urgent field safety notice looking to recall select coronary dilation and balloon catheters over issues with inflating and deflating the balloons. The company said it is recalling specific lots of the NC Trek RX coronary dilation catheter, the NC Traveler RX coronary dilation catheter and the NC Tenku RX PTCA balloon catheter over issues with removing the protective balloon sheath which can result in issues inflating or deflating the balloon. Risks associated with inflation and deflation issues include air embolism, thrombosis, myocardial infarction and may require additional interventi...
Source: Mass Device - April 21, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Catheters Recalls Abbott Source Type: news

Focused issue on vascular disease in women available now
(SAGE) Vascular disease is a leading cause of morbidity and death worldwide. There are important sex-related differences in risk factors, clinical manifestations, and therapeutic outcomes in peripheral vascular diseases, including peripheral artery disease (PAD), venous thromboembolism (VTE), and aortic disease. In addition, some vascular conditions predominantly affect women. With this in mind, Vascular Medicine, the official journal of the Society for Vascular Medicine, dedicated its April 2017 issue to the topic of Vascular Disease in Women. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 21, 2017 Category: Global & Universal Source Type: news

Even Short-term Oral Steroids Carry Serious Risk Even Short-term Oral Steroids Carry Serious Risk
A large, population-based study found a significantly higher rate of acute adverse events such as sepsis, venous thromboembolism, and fracture, even after a low-dose, short-term steroid treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 20, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Medtronic Signs Definitive Agreement to Divest a Portion of Its Patient Monitoring and Recovery Division to Cardinal Health for $6.1 Billion
DUBLIN - April 18, 2017 -- (Healthcare Sales & Marketing Network) -- Medtronic plc (NYSE: MDT) today announced that it has entered into a definitive agreement with Cardinal Health Inc. (NYSE: CAH) to sell its Patient Care, Deep Vein Thrombosis, and Nutriti... Devices, Acquisitions Medtronic, Cardinal Health, Deep Vein Thrombosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 18, 2017 Category: Pharmaceuticals Source Type: news

Cardinal Health buying medical supplies business from Medtronic for $6.1 billion
Cardinal Health Inc. is buying several medical product lines from Medtronic for $6.1 billion in cash. In the deal with the medical-device giant, Dublin-based Cardinal (NYSE:CAH) has agreed to buy Medtronic's patient care, deep vein thrombosis and nutritional insufficiency lines. The company said the lines include 23 product categories and several well-established brands used in nearly every U.S. hospital, including Curity, Kendall, Dover, Argyle and Kangaroo. The deal had been suspected; Medtronic… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 18, 2017 Category: Pharmaceuticals Authors: Doug Buchanan Source Type: news